EMD Millipore Opens New R&D Center
The facility, which includes state-of-the-art formulation, analytical and synthetic laboratories as well as a customer training center, will focus on bioavailability enhancement and oral dosage formulations.
EMD Millipore announced that it has opened a new R&D center for formulation in Darmstadt, Germany, which combines state-of-the-art formulation, analytical and synthetic laboratories and a customer training center in a single facility.
With EMD Millipore’s expertise in developing oral dosage formulations and drug delivery systems, the center will focus on addressing bioavailability and formulation challenges by using the company’s portfolio of innovative technologies and products. It will provide hands-on support to assist customers in their drug development.
EMD Millipore’s core areas are inorganic carriers, solid dispersion formulation techniques and excipients for controlled release, with technologies in granulation, tableting, film coating, direct compression and freeze drying.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Pfizer Obtains Exclusive Rights to 3SBio’s Bispecific Antibody Targeting PD-1 and VEGF
July 25th 2025The licensing agreement between the two companies gives Pfizer the rights to develop, manufacture, and commercialize 3SBio’s bispecific antibody, SSGJ-707, which is in clinical trials for the treatment of a variety of cancers.
